AgomAb Therapeutics NV (AGMB) vs Protalix BioTherapeutics (DE) (PLX)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
AgomAb Therapeutics NV is the larger company by market cap ($268.4 million vs $244.5 million), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | AGMB | PLX |
|---|---|---|
| Share price | $5.45 | $2.90 |
| Market cap | $268.40M | $244.52M |
| 1-day change | -3.02% | -5.23% |
| YTD return | — | +61.11% |
| 1-year return | — | +65.71% |
| 5-year return | — | +192.93% |
| P/E ratio (TTM) | — | 12.08 |
| Forward P/E | — | 4.68 |
| EPS (TTM) | $-2.08 | $0.24 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | — | $52.74M |
| Revenue growth (YoY) | — | -1.23% |
| Net income (latest FY) | — | $-6.60M |
| Gross margin | — | 48.82% |
| Operating margin | — | -10.43% |
| Net margin | — | -12.52% |
| 52-week high | $17.82 | $3.19 |
| 52-week low | $5.39 | $1.65 |
| Distance from 52-week high | -69.42% | -9.09% |
| Analyst consensus | strong_buy | strong_buy |
| Avg. price target upside | +591.19% | +313.79% |
| Average volume | 208.99K | 903.48K |
| Shares outstanding | 49.25M | 84.32M |
| Employees | 62 | 226 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Biological Products (No Diagnostic Substances) |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
About AgomAb Therapeutics NV
AGMB stock →AgomAb Therapeutics NV, a clinical-stage biopharmaceutical company, develops novel disease-modifying therapies for immunology and inflammatory diseases in the United States. The company's product pipeline includes Ontunisertib (AGMB-129), an oral gastrointestinal-restricted small molecule inhibitor of ALK5 or TGFßR1 for the treatment of Fibrostenosing Crohn's disease, which is in Phase 2a clinical trials; and AGMB-447, an inhaled small molecule inhibitor of ALK5 or TGFßR1 for the treatment of idiopathic pulmonary fibrosis that is in Phase 1 clinical trials.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 62 employees
About Protalix BioTherapeutics (DE)
PLX stock →Protalix BioTherapeutics, Inc., a biopharmaceutical company, engages in the development, production, and commercialization of recombinant therapeutic proteins based on the ProCellEx plant cell-based protein expression system. The company provides Elelyso for the treatment of Gaucher disease; and Elfabrio for the treatment of adult patients with a confirmed diagnosis of Fabry disease.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 226 employees
AGMB vs PLX FAQ
Which is bigger, AgomAb Therapeutics NV or Protalix BioTherapeutics (DE)?
AgomAb Therapeutics NV (AGMB) is larger, with a market capitalization of $268.40M compared with $244.52M for Protalix BioTherapeutics (DE) (PLX).
Are AgomAb Therapeutics NV and Protalix BioTherapeutics (DE) in the same industry?
Yes. Both are classified in the Biotechnology: Biological Products (No Diagnostic Substances) industry within the Health Care sector.